These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 1880653)
1. Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease. Greene HL; Swift LL; Knapp HR J Pediatr; 1991 Sep; 119(3):398-403. PubMed ID: 1880653 [TBL] [Abstract][Full Text] [Related]
2. Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk. Nagasaka H; Hirano K; Ohtake A; Miida T; Takatani T; Murayama K; Yorifuji T; Kobayashi K; Kanazawa M; Ogawa A; Takayanagi M Eur J Pediatr; 2007 Oct; 166(10):1009-16. PubMed ID: 17206455 [TBL] [Abstract][Full Text] [Related]
3. Plasma and lipoprotein fatty acid composition in glycogen storage disease type I. Levy E; Letarte J; Lepage G; Thibault L; Roy CC Lipids; 1987 Jun; 22(6):381-5. PubMed ID: 3475522 [TBL] [Abstract][Full Text] [Related]
5. Glycogen storage disease type Ia: linkage of glucose, glycogen, lactic acid, triglyceride, and uric acid metabolism. Sever S; Weinstein DA; Wolfsdorf JI; Gedik R; Schaefer EJ J Clin Lipidol; 2012; 6(6):596-600. PubMed ID: 23312056 [TBL] [Abstract][Full Text] [Related]
6. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282 [No Abstract] [Full Text] [Related]
7. Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. Wolfsdorf JI; Crigler JF J Pediatr Gastroenterol Nutr; 1999 Aug; 29(2):136-43. PubMed ID: 10435649 [TBL] [Abstract][Full Text] [Related]
8. Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control. Peeks F; Steunenberg TAH; de Boer F; Rubio-Gozalbo ME; Williams M; Burghard R; Rajas F; Oosterveer MH; Weinstein DA; Derks TGJ J Inherit Metab Dis; 2017 Sep; 40(5):695-702. PubMed ID: 28397058 [TBL] [Abstract][Full Text] [Related]
9. A monocentric pilot study of an antioxidative defense and hsCRP in pediatric patients with glycogen storage disease type IA and III. Kalkan Ucar S; Coker M; Sözmen E; Goksen Simsek D; Darcan S Nutr Metab Cardiovasc Dis; 2009 Jul; 19(6):383-90. PubMed ID: 19073362 [TBL] [Abstract][Full Text] [Related]
10. ATP depletion, a possible role in the pathogenesis of hyperuricemia in glycogen storage disease type I. Greene HL; Wilson FA; Hefferan P; Terry AB; Moran JR; Slonim AE; Claus TH; Burr IM J Clin Invest; 1978 Aug; 62(2):321-8. PubMed ID: 276529 [TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine (ADMA) and L-arginine levels in children with glycogen storage disease type I. Kasapkara ÇS; Tümer L; Biberoglu G; Kasapkara A; Hasanoğlu A J Pediatr Endocrinol Metab; 2013; 26(5-6):427-31. PubMed ID: 23412857 [TBL] [Abstract][Full Text] [Related]
12. An association among iron, copper, zinc, and selenium, and antioxidative status in dyslipidemic pediatric patients with glycogen storage disease types IA and III. Kalkan Ucar S; Coker M; Sözmen E; Goksen Simsek D; Darcan S J Trace Elem Med Biol; 2010 Jan; 24(1):42-5. PubMed ID: 20122579 [TBL] [Abstract][Full Text] [Related]
13. Continuous glucose monitoring in children with glycogen storage disease type I. Kasapkara ÇS; Cinasal Demir G; Hasanoğlu A; Tümer L Eur J Clin Nutr; 2014 Jan; 68(1):101-5. PubMed ID: 24149443 [TBL] [Abstract][Full Text] [Related]
14. Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions. Derks TG; van Rijn M J Inherit Metab Dis; 2015 May; 38(3):537-43. PubMed ID: 25633903 [TBL] [Abstract][Full Text] [Related]
15. Sustained high plasma mannose less sensitive to fluctuating blood glucose in glycogen storage disease type Ia children. Nagasaka H; Yorifuji T; Bandsma RH; Takatani T; Asano H; Mochizuki H; Takuwa M; Tsukahara H; Inui A; Tsunoda T; Komatsu H; Hiejima E; Fujisawa T; Hirano K; Miida T; Ohtake A; Taguchi T; Miwa I J Inherit Metab Dis; 2013 Jan; 36(1):75-81. PubMed ID: 22971957 [TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for glycogen storage disease type Ia. Reddy SK; Austin SL; Spencer-Manzon M; Koeberl DD; Clary BM; Desai DM; Smith AD; Kishnani PS J Hepatol; 2009 Sep; 51(3):483-90. PubMed ID: 19596478 [TBL] [Abstract][Full Text] [Related]
17. Preemptive living donor liver transplantation in glycogen storage disease Ia: case report. Kaihara S; Ushigome H; Sakai K; Yoshizawa A; Nobori S; Suzuki T; Okamoto M; Ochiai T; Yoshimura N Transplant Proc; 2008 Oct; 40(8):2815-7. PubMed ID: 18929868 [TBL] [Abstract][Full Text] [Related]
18. Cornstarch requirements of the adult glycogen storage disease Ia population: A retrospective review. Dahlberg KR; Ferrecchia IA; Dambska-Williams M; Resler TE; Ross KM; Butler GL; Kuo CL; Ryan PT; Weinstein DA J Inherit Metab Dis; 2020 Mar; 43(2):269-278. PubMed ID: 31415093 [TBL] [Abstract][Full Text] [Related]
19. Secondary metabolic changes in von Gierke's disease (Type I glycogen storage disease). Blackett PR Ann Clin Lab Sci; 1982; 12(5):424-30. PubMed ID: 6753728 [TBL] [Abstract][Full Text] [Related]
20. Glycogen storage disease type 1: impact of medium-chain triglycerides on metabolic control and growth. Das AM; Lücke T; Meyer U; Hartmann H; Illsinger S Ann Nutr Metab; 2010; 56(3):225-32. PubMed ID: 20357432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]